Publications found:
12,815
Sort by:
Indian Smart Card Market Report & Forecast: 2011-2016
US$ 1,400.00
India, which has historically been lagging behind the West and other major Asian countries in the use of smart cards, is currently at the threshold of a revolution. Smart cards are not only rapidly re...
December 2011
85 pages
LUPIN - Lupin - Loss of 2 Exclusivities Further Exposes the weak Pipeline
US$ 140.00
... . Most glaring is the Fortmet case, where Lupin launched the product ‘at-risk’ and later withdrew ... settled with Lupin it cannot launch its generic version (unless ‘at-risk’) thereby leading to a loss of this ... shared 180-day exclusivity for Lupin. These add to the pressure ...
December 2011
3 pages
Indian Payment Card Market Forecast to 2012
US$ 800.00
India has witnessed tremendous rise in middle-class households and shift in the spending pattern of consumers that has boosted the growth of Indian payment card market, including credit, debit, and pr...
November 2011
75 pages
Indian Tyre Industry Analysis
US$ 800.00
India has emerged as one of the world’s most competitive tyre markets due to vast availability of raw material (natural rubber) and ultramodern production facilities. However the FY 2009 was a quite d...
November 2011
70 pages
Indian Intelligent Building Management Systems Market (2011 – 2016)
US$ 5,650.00
... North India, South India, East India, and West India. The Indian IBMS market report, as the name suggests, illustrates the Indian scenario in face of intelligent buildings and building management systems over the next five years with insights into: The demand side of the market Much more interactive customers demanding intelligent ...
November 2011
208 pages
Dyestuff Market in India 2011
US$ 950.00
... after order is placed. India is considered to be ranked 6th globally in terms of chemical industry volumes. Dyestuff market is under strict environmental ... along with production volume of dyestuff units in India. This is followed by a brief on the major segments in the dyestuff market as well as an analysis ...
November 2011
46 pages
SUN PHARMA - A structural improvement at play
US$ 140.00
Sun’s Q2 FY12 result was much higher than our and street’s ... after acquisition of 100% stake. We thus rate Sun Pharma as our top pick in the large cap India pharma. We will change our estimate later to incorporate ...
November 2011
7 pages
CADILA HEALTHCARE - Still Carrying The Burden of The High Base Last Year
US$ 140.00
Cadila’s Q2 FY12 result was below our estimate (adjusted to ... for muted growth in markets like India and Emerging Markets, we believe that the growth is still impacted due to the high ... the markets. We thus do not see any structural issues with Cadila. In addition, USFDA approval of its Baddi facility comes as a ...
November 2011
5 pages
DISHMAN - Downward Guidance Revision – No More An Exception
US$ 140.00
Dishman once again reported quarterly result much below our and ... . Thus debt repayment can happened only through asset sale. We revise our FY 12 earnings estimates down by 28%. Consequently we cut our target price ...
November 2011
5 pages
RANBAXY - Moderate Improvement In Base Business
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after Q3 CY11 result that was largely in line with our ... the low base of EBITDA margin, the improvement was expected to be slightly higher especially as Ranbaxy has shut down most of its loss making ...
November 2011
6 pages
AUROBINDO - A Washout Result
US$ 140.00
Aurobindo’s Q2 FY12 result was much below our expectations with almost complete washout on every parameter. While formulation sales, income from dossier, gross ...
November 2011
6 pages
LUPIN - Margin Pressure Highlight The Weakness of US Portfolio
US$ 140.00
... on Lupin after its Q2FY12 result that was largely in line with our estimates. Ex-Medicis milestone income, sales growth (up 17%) and gross margin ... of one per quarter and (3) Suprax growing by 43% Y-o-Y. We believe all these highlights (1) the dependence on generic Lotrel (2) increased sales force expense for ...
November 2011
6 pages
Indian Aerospace Supply Chain Market: 2011, October 2011
US$ 2,900.00
... Indian Aerospace Supply Chain Market: 2011” are- Indian aerospace industry overview Market size ($) at various structural levels (Tier I, Tier II, and OEM) Indian aerospace market in terms of ($) value shipment Supply Chain evolution of Indian aerospace ...
November 2011
78 pages
Booming Biotech Market in India
US$ 800.00
Indian biotech sector is witnessing a quantum surge in terms of growth of the industry. The growth can be attributed to a large pool of scientific talent, world-class information technology industry,...
October 2011
100 pages
CIPLA, Para IV Upside To Continue: Its Lexapro After Zyprexa
US$ 350.00
... of $1b) under 180-day exclusivity starting 14 March 2012. Cipla remained an active partner to Ivax (now Teva) by developing ... -day exclusivity. Thus Cipla too will share the upsides from the exclusivity. We expect Cipla to gain $50m ... will start accruing immediately after the upside from Zyprexa API supply to Teva ...
October 2011
3 pages
Indian Natural Gas Sector Analysis
US$ 800.00
India’s primary energy basket is on the threshold of witnessing a quantum jump in contribution from natural gas to meet soaring domestic energy demand. Due to the inherent environment-friendly nature,...
September 2011
110 pages
Indian Power Sector Analysis
US$ 800.00
Being one of the fastest growing economies and the second largest populated country, India represents an attractive destination for the power industry. The working age population is increasing at a ra...
September 2011
105 pages
Indian Energy Sector 2011-2020: Economic and Risk Analysis, September 2011
US$ 2,490.00
... to Lucintel`s report "Indian Energy Sector 2011-2020: Economic and Risk Analysis", analyzes and identifies India`s energy sector and outlines its areas of opportunity in the coming decade. Energy consumption from ... to Lucintel’s report "Indian Energy Sector 2011-2020: Economic and Risk Analysis", analyzes and identifies India’s energy sector and outlines its areas of opportunity in the coming decade. Energy consumption from ...
September 2011
230 pages
Booming Clinical Trials Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 India has billion plus population and a home for various life threate...
August 2011
145 pages
Booming Consumer Electronics Market in India
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 The Indian consumer electronics industry has been growing at a double-digit...
August 2011
95 pages
Booming Generics Drug Market in India
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 The world has witnessed a sharp increase in the demand for cost-effec...
August 2011
60 pages
Indian Fast Food Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 The Indian fast food market has been witnessing rapid growth on the back of positive d...
August 2011
40 pages
India Solid Waste Management Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,100.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 India being the 7th largest country in terms of area and 2nd largest in terms of populatio...
August 2011
65 pages
Indian Cement Market Report: 2011 Edition
US$ 800.00
... and construction recovery. Even in the tough conditions, Indian cement industry has been able to sustain its growth. ... cement companies. The report analyzes the cement industry in India focusing on demand supply matrix in various regions. The report is aimed at providing a better understanding of the market ...
August 2011
45 pages
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Hair Color Market in India 2011
US$ 950.00
... after order is placed. The hair color market in India is driven by growth in the need to not only cover grey hairs and look presentable but also ... also been highlighted. This is followed by an overview of the hair color market in India. The section talks of the market size and growth of the sector and provides ...
August 2011
38 pages
Aurobindo - Feeling The Heat of USFDA and Debt
US$ 140.00
We reiterate our Underperform rating on Aurobindo after Q1 FY12 result that remained ... (up by 39% and 20% of total sales) that included a Government of India tender where ARBP did not earn any profit. As expected ... API and formulations) remain at the core of ‘India advantage’. We reduce our target price to Rs.120
August 2011
6 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
Sun Pharma- Strong Margin Indicates A Strong Product Portfolio
US$ 140.00
Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...
August 2011
8 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Biocon – Uneventful Quarter – R&D Expense Yet To Rise
US$ 140.00
BIOS 4QFY11 result was below our expectations on sales (excluding licensing income), but met our earnings estimate largely due to a lower than expected R&D expense. Licensing income too remained below estimate as it remains lumpy. Surprisingly biopharma sales (ex licensing income) grew by a modest 9% mainly ...
July 2011
6 pages
Direct-to-Home (DTH) Market in India: 2011 Edition
US$ 800.00
Direct-to-Home (DTH) is a distribution platform for multichannel TV programs on KU band by using a satellite system which transmits signal directly to the subscriber’s premises. ... satellites and content. The major players in DTH market in India are Dish TV, Tata Sky, Sun Direct, Big TV, Airtel Digital TV and ...
July 2011
40 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
... cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume ... world’s top 11 products under litigation. This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the ...
June 2011
214 pages
Indian Diagnostic Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1400.00 Hard Copy: US$ 1000.00 CD-ROM: US$ 1000.00Indian diagnostics sector is witnessing an era of immense progress in innovative competenc...
June 2011
65 pages
Indian Education Services - A Hot Opportunity
US$ 900.00
Single User PDF Format: US$ 900.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00India has one of the largest higher education systems in the world. However, still ther...
June 2011
80 pages
Indian MVAS Market Forecast to 2014
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 India mobile value-added services (MVAS) market has been witnessing phenomenal growth...
June 2011
55 pages
India 3G Market Forecast to 2014
US$ 600.00
Single User PDF Format: US$ 600.00 Multi-User License: US$ 1,000.00 Hard Copy: US$ 700.00 CD-ROM: US$ 700.00 The Indian telecom industry has undergone a revolutionary change during the past few years...
June 2011
60 pages
Indian Tourism Industry Analysis
US$ 600.00
Single User PDF Format: US$ 600.00 Multi-User License: US$ 900.00 Hard Copy: US$ 700.00 CD-ROM: US$ 700.00 Indian tourism sector is one of the most crucial sectors of the economy in the country. It i...
June 2011
60 pages
